A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity

Overview of attention for article published in Frontiers in oncology, September 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 5 news outlets
twitter: 2 X users

patent: 1 patent

Citations

dimensions_citation: 17 Dimensions

Readers on

mendeley: 32 Mendeley

Summary News X Patents Dimensions citations

So far, Altmetric has seen 6 news stories from 5 outlets.

News story from Finanz Nachrichten on Tuesday 02 October 2018

Finanz Nachrichten, 02 Oct 2018

Preclinical Efficacy Data of Apogenix' HERA-CD27L Published in Frontiers in Oncology — BioPortfolio.com

Bioportfolio, 02 Oct 2018

DGAP-News: Apogenix AG / Key word(s): Scientific publication 02.10.2018 / 10:00 The issuer is solely responsible for the…

Preclinical Efficacy Data of Apogenix' HERA-CD27L

Direkt Broker , 02 Oct 2018

Published in Frontiers in Oncology HERA-CD27L Enhances T Cell Activation and Induces Anti-Tumor Immunity Heidelberg, Germany…

Apogenix AG,

Ad Hoc News, 02 Oct 2018

Präklinische Daten zur Wirksamkeit von Apogenix' HERA-CD27L in Frontiers in Oncology veröffentlicht Präklinische Daten zur…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 2 additional news stories.